banner

News Releases

Date Title and Summary  
Toggle Summary ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
ACADIA to Host Conference Call and Webcast on Wednesday, February 26, 2020 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40 th Annual Health Care Conference in Boston on Monday, March 2, 2020 , at 2:10 p.m. Eastern Time . A live webcast of ACADIA’s presentation will be
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
- Full Year 2019 Net Sales Grew to $339.1 Million , a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million - On-Track to Submit Supplemental New Drug Application for Dementia-Related Psychosis in Summer 2020 SAN DIEGO --(BUSINESS WIRE)--Feb.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need SAN DIEGO & MELBOURNE, Australia --(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2020 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 15, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020 , after the close of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--May 5, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences: 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020 , at 11:00 a.m. Eastern Time .
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
- ACADIA acquires exclusive worldwide rights to a novel therapeutic program targeting muscarinic M1 receptors SAN DIEGO & NASHVILLE, Tenn. --(BUSINESS WIRE)--May 7, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
- 1Q20 Net Sales of $90.1 Million , a 43% Increase Over 1Q19 - On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer - Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--May 21, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
- Top-line results expected in 3Q20 SAN DIEGO --(BUSINESS WIRE)--May 26, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
SAN DIEGO --(BUSINESS WIRE)--May 28, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 2, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 , at 4:40 p.m. Eastern Time . The conference will be held virtually.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- Submission based on positive results from the Phase 3 HARMONY study which showed a statistically significant 2.8 fold reduction in the risk of relapse of psychosis SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a
Printer Friendly Version